BGB
Bergenbio
Stock
Stock
ISIN: NO0013251173
Ticker: BGBIO
NO0013251173
BGBIO
Price
Price
CHART BY
Frequently asked questions
What is Bergenbio's market capitalization?
The market capitalization of Bergenbio is $4.47M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Bergenbio?
Bergenbio's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.406. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Bergenbio's stock?
Currently, 1 analysts cover Bergenbio's stock, with a consensus target price of $3.765. Analyst ratings provide insights into the stock's expected performance.
What is Bergenbio's revenue over the trailing twelve months?
Over the trailing twelve months, Bergenbio reported a revenue of $84.01K.
What is the EBITDA for Bergenbio?
Bergenbio's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$15.38M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Bergenbio?
Bergenbio has a free cash flow of -$14.83M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Bergenbio have, and what sector and industry does it belong to?
Bergenbio employs approximately 13 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Bergenbio's shares?
The free float of Bergenbio is 25.47M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $4.47M
- EPS (TTM)
- -$0.406
- Free Float
- 25.47M
- Revenue (TTM)
- $84.01K
- EBITDA (TTM)
- -$15.38M
- Free Cashflow (TTM)
- -$14.83M
Pricing
- 1D span
- $0.114$0.115
- 52W span
- $0.0996$1.404
Analyst Ratings
The price target is $3.765 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. It focuses on developing a pipeline of AXL kinase inhibitors. Its lead product bemcentinib, is a selective and orally bio-available small molecule AXL inhibitor. The company was founded by James Bradley Lorens and David R. Micklem on December 21, 2007 and is headquartered in Bergen, Norway.
- Employees
- 13
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- NO0013251173
- Primary Ticker
- BGBIO
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet